This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Scotiabank Keeps Their Buy Rating on Teva Pharmaceutical (TEVA)

Tipranks - Tipranks - Thu Jul 9, 7:02AM CDT

Scotiabank analyst Louise Chen maintained a Buy rating on Teva Pharmaceutical today and set a price target of $40.00.

55% Off TipRanks

Chen covers the Healthcare sector, focusing on stocks such as Gilead Sciences, Merck & Company, and Pfizer. According to TipRanks, Chen has an average return of 5.0% and a 49.69% success rate on recommended stocks.

Teva Pharmaceutical has an analyst consensus of Strong Buy, with a price target consensus of $42.38.

See the top stocks recommended by analysts >>

Based on Teva Pharmaceutical’s latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $3.98 billion and a net profit of $369 million. In comparison, last year the company earned a revenue of $3.89 billion and had a net profit of $214 million

Based on the recent corporate insider activity of 64 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of TEVA in relation to earlier this year. Last month, Matthew Shields, the EVP, Global Operations of TEVA sold 9,989.00 shares for a total of $321,545.91.

Read More on TEVA:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).